

9 September 2021

The Manager
ASX Announcements
Australian Securities Exchange
Level 4
20 Bridge Street
Sydney NSW 2000

Dear Sir / Madam

ASX Appendix 3Y

The Company refers to the ASX release dated 9 September 2021 confirming the vesting of various restricted stock units for the Company's Chief Executive Officer, Dr Mike Perry, in connection with the fulfilment of the relevant vesting milestone.

Pursuant to the above, please find attached an ASX Appendix 3Y recording a change in Dr Perry's interests in the Company.

Please note that the disposal of shares by Dr Perry by way of an on market sale (as reflected in the attached ASX Appendix 3Y) was executed solely for the purposes of satisfying Dr Perry's income tax liability payable to the U.S. Internal Revenue Service and various State tax authorities (i.e. all sales are solely to cover income tax liability).

Authorized by

Michael Holder

Michael Holder
Chief Financial Officer

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	AVITA Medical, Inc ("Avita US")
ARBN	641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael Perry
Date of last notice	8 June 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable
Date of change	1 September 2021 (United States)

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>634,602 CHESSE Depository Interests (“CDIs”) in Avita US quoted on ASX (representing beneficial ownership of 126,920 shares of common stock in Avita US).</p> <p>50,677 shares of common stock in Avita US quoted on the NASDAQ Stock Market LLC.</p> <p>Dr Perry also held the following convertible securities in AVITA Medical Pty Limited ACN 058 466 523 (“Avita Australia”), being a wholly owned subsidiary of Avita US, prior to the change:</p> <ul style="list-style-type: none"> • 15,000,000 unquoted options in Avita Australia (consolidation equivalent = 150,000 unquoted options in Avita US) • 9,501,400 unquoted restricted stock units (“RSUs”) in Avita Australia (consolidation equivalent = 95,014 unquoted RSUs in Avita US). <p>The convertible securities held in Avita Australia entitle Dr Perry, upon vesting of their conversion rights, to be issued shares of common stock in Avita US (which may be represented by CDIs) rather than ordinary shares in Avita Australia on a consolidation ratio of 100:1 as set out in Avita US’s pre-quotations disclosure released to the market on 24 June 2020.</p>
<p>Class</p>	<p>As above</p>
<p>Number acquired</p>	<p>23,754 shares of common stock in Avita US (which do not presently have CDIs issued over them and therefore are not quoted on ASX) acquired on 1 September 2021 (United States).</p>

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Number disposed	11,220 shares of common stock in Avita US disposed of on 1 September 2021 (United States). 2,375,400 unquoted RSUs in Avita Australia (consolidation equivalent = 23,754 RSUs in Avita US) which were converted into 23,754 shares of common stock in Avita US that were issued on 1 September 2021 (United States).
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Disposal of 11,220 shares of common stock in Avita US – US\$20.62 per share of common stock (being the average price per share of common stock sold). Acquisition of 23,754 shares of common stock in Avita US – nil consideration (issued as a result of the vesting of the relevant tranche of Dr Perry's unquoted RSUs in Avita Australia).

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held after change</p>	<p>634,602 CDIs in Avita US quoted on ASX (representing beneficial ownership of 126,920 shares of common stock in Avita US).</p> <p>63,211 shares of common stock in Avita US quoted on the NASDAQ Stock Market LLC.</p> <p>Dr Perry also holds the following convertible securities in Avita Australia, being a wholly owned subsidiary of Avita US:</p> <ul style="list-style-type: none"> • 15,000,000 unquoted options in Avita Australia (consolidation equivalent = 150,000 unquoted options in Avita US) • 7,126,049 unquoted RSUs in Avita Australia (consolidation equivalent = 71,260 unquoted RSUs in Avita US). <p>The convertible securities held in Avita Australia entitle Dr Perry, upon vesting of their conversion rights, to be issued shares in Avita US (which may be represented by CDIs) rather than ordinary shares in Avita Australia on a consolidation ratio of 100:1 as set out in Avita US's pre-quotations disclosure released to the market on 24 June 2020.</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Disposal on 1 September 2021 (United States) - on market sale</p> <p>Acquisition on 1 September 2021 (United States) – conversion of unquoted RSUs in Avita Australia</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<p>Detail of contract</p>	<p>Not applicable</p>
----------------------------------	-----------------------

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	Not applicable
Interest after change	Not applicable

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.

For personal use only